CN101062097A - Compound for improving and treating fatty liver disease - Google Patents
Compound for improving and treating fatty liver disease Download PDFInfo
- Publication number
- CN101062097A CN101062097A CNA2007102008031A CN200710200803A CN101062097A CN 101062097 A CN101062097 A CN 101062097A CN A2007102008031 A CNA2007102008031 A CN A2007102008031A CN 200710200803 A CN200710200803 A CN 200710200803A CN 101062097 A CN101062097 A CN 101062097A
- Authority
- CN
- China
- Prior art keywords
- extract
- weight percentage
- fructus schisandrae
- schisandrae chinensis
- monas cuspurpureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 20
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 20
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 20
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 30
- 244000113306 Monascus purpureus Species 0.000 claims description 30
- 229940057059 monascus purpureus Drugs 0.000 claims description 30
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 23
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 23
- 229960004844 lovastatin Drugs 0.000 claims description 23
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 23
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 22
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 22
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 claims description 21
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 claims description 21
- 229960004245 silymarin Drugs 0.000 claims description 21
- 235000017700 silymarin Nutrition 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 15
- 230000003212 lipotrophic effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 244000272459 Silybum marianum Species 0.000 abstract 1
- 235000010841 Silybum marianum Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 239000002994 raw material Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 description 1
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 description 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- KDMGQPNVTKUNHV-UHFFFAOYSA-N Isosilybin Natural products C1=C(O)C(OC)=CC=C1C1C(CO)OC2=CC=C(C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)C=C2O1 KDMGQPNVTKUNHV-UHFFFAOYSA-N 0.000 description 1
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- RIAZZJBPJQWPIS-UHFFFAOYSA-N Silychristin Natural products COc1cc(ccc1O)C2OC3C(C=C(C=C3O)C4Oc5cc(O)cc(O)c5C(=O)C4O)C2CO RIAZZJBPJQWPIS-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 1
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000010271 massa medicata fermentata Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229950004304 silidianin Drugs 0.000 description 1
- SEBFKMXJBCUCAI-DBMPWETRSA-N silybin Chemical compound C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-DBMPWETRSA-N 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 description 1
- BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 description 1
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicinal composition for preventing and treating fatty liver, wherein the composition comprises Monascus color extract, schisandra fruit extract and Silybum marianum extract.
Description
Technical field
The invention belongs to field of medicaments, particularly relate to a kind of improvement and lipotropic compositions.
Background technology
Fat accounts for 3%～5% of liver gross weight under the normal condition.1/10 or the histology that surpass liver weight when fat content are fatty liver when upward hepatocyte fatties more than half become.Its pathogenesis is not clear and definite fully as yet so far, it is generally acknowledged that the imbalance that hepatocyte is synthesized between triacylglycerol and the secretion very low density lipoprotein (VLDL) is the main cause that forms fatty liver, and this imbalance is because due to increase of hepatocyte lipogenesis or the oxidation minimizing.Change along with living habit and dietary structure, the enhancing of health care consciousness, the progress of detection means, the sickness rate and the recall rate of fatty liver increase gradually, become the common hidden danger of a serious harm human body health, the certain areas fatty liver has become the second largest hepatopathy that is only second to viral hepatitis.According to American-European scholar's statistics, the pathogenesis of fatty liver rate accounts for 10%～24% general crowd, accounts for 57.5%～74% in the overweight people.In China, according to geographic part survey results such as Beijing, Shanghai and Nanjing, Hangzhou, Lianyun Harbour, Jiangsu, sickness rate does not wait between 5.2%～11.4%, and wherein the male is higher than the women, and age of onset has more and more littler trend.Significant be the incidence rate of discovering in non-alcoholic fatty liver disease (NAFL) hepatic fibrosis to be arranged up to 25%.Wherein 1.5%～8.0% patient can make progress and is hepatitis interstitialis chronica, and causes a series of severe complications, be considered to the latent cirrhotic commonly encountered diseases of source property because of.Therefore, lipotropism more and more causes people's attention.Present western medicine fatty liver or existence toxicity in various degree, or lipid-lowering effect is undesirable. and regular meeting's bounce-back affects the treatment after the drug withdrawal, so, be restricted aspect the fibrosis of its development of control and liver for a kind of like this chronic disease of fatty liver.The fatty liver traditional Chinese medical science does not have this name of disease, belongs to " gathering " categories such as " lump at the left hypochondrium " more, belongs to the disease of liver spleen, as " interior warp " institute cloud: " liver is long-pending, day lump at the left hypochondrium ".Think that this disease is to eat the delicious food savoury owing to having a liking for for a long time, insobriety or lying on bed for a long time sitting, the rich expectorant of body is full of, or internal injury caused by excess of seven emotions, it is improper to take good care of oneself, and makes spleen lose fortuneization, the liver failing to maintain the normal flow of QI, organism metabolic disorder, it is little that water paddy can not change spermatogenesis, poly-and be the wet expectorant that is, stasis of blood resistance liver network and form this disease.Chinese medicine fatty liver curative effect steadily, the advantage of multidirectional adjusting is arranged, more to the research of Chinese medicine decoction treatment fatty liver in recent years.Up to now, for the treatment of fatty liver, all do not finding satisfied fully therapeutic scheme aspect the traditional Chinese medical science and the doctor trained in Western medicine.
Summary of the invention
The object of the present invention is to provide a kind of improvement and lipotropic compositions, this compositions has blood lipid regulation, liver-protective effect, and toxic and side effects is little.
In a kind of improvement and lipotropic compositions involved in the present invention, contain Monas cuspurpureus Went extract, Fructus Schisandrae Chinensis extrat and Herba Silybi mariani extract.
Monas cuspurpureus Went extract is 0.02～20% in its weight percentage of lovastatin in the compositions, Fructus Schisandrae Chinensis extrat is 0.05～30% in its weight percentage of schisandrin B, and Herba Silybi mariani extract is 0.05～50% in its weight percentage of silymarin.
Monas cuspurpureus Went extract is 0.1～5% in the lovastatin weight percentage in the preferred composition, and Fructus Schisandrae Chinensis extrat is 0.2～10% in the schisandrin B weight percentage, and Herba Silybi mariani extract is 0.2～20% in the silymarin weight percentage.
Further Monas cuspurpureus Went extract is 1% in the lovastatin weight percentage in the preferred composition, and Fructus Schisandrae Chinensis extrat is 2% in the schisandrin B weight percentage, and Herba Silybi mariani extract is 10% in the silymarin weight percentage.
Described Monas cuspurpureus Went extract is a main active with the lovastatin, and lovastatin accounts for 0.4～99% by weight percentage in the Monas cuspurpureus Went extract; Described Fructus Schisandrae Chinensis extrat is a main active with the schisandrin B, and schisandrin B accounts for 5～99% by weight percentage in the Fructus Schisandrae Chinensis extrat; Described Herba Silybi mariani extract is a main active with the silymarin, and silymarin accounts for 40～99% by weight percentage in the Herba Silybi mariani extract.
Described compositions is made acceptable dosage form clinically with acceptable adjuvant medically.
The dosage form of described compositions can be tablet, capsule, granule, powder, pill, drop pill, mixture, injection and other clinical acceptable preparation.
The preparation of described compositions can be ordinary preparation, quick releasing formulation, sustained-release preparation and other clinical acceptable preparation.
Described compositions is improved and control fatty liver medicine and the application in accent fat liver-protecting health food in preparation.
The sweet temperature of Monas cuspurpureus Went is gone into hepatosplenomegaly intestinal warp, energy blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion.Monas cuspurpureus Went head sees principle of Correct Diet, claims its sweet in the mouth flat, nontoxic, and the effect of spleen invigorating, QI invigorating, warming middle-JIAO is arranged; " Bencao Jingshu " says that it helps digestion, spleen invigorating is identical with Massa Medicata Fermentata, and invigorates blood circulation and hinder, and is can with the Monas cuspurpureus Went; " Amplification on Materia Medica addendum " claims it to invigorate blood circulation to help digestion the spleen invigorating warming the stomach; " Chinese medicine dictionary " claims its energy blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion, treatment prolonged lochia, the stagnant stomachache of the stasis of blood, glutted, the red white dysentery of food stagnation and traumatic injury.Modern pharmacology confirms that Monas cuspurpureus Went can act on lipometabolic different link, as absorption by the exogenous cholesterol of interference, suppress the metabolism of endogenous cholesterol, be rich in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and multiple unsaturated fatty acid, TC and TG be can effectively reduce, and multiple essential amino acids and trace element in the human body contained.Effective ingredient lovastatin in the Monas cuspurpureus Went is used for the treatment of hyperlipidemia, is one of world's situation of selling well medicine.The effect of Monas cuspurpureus Went extract is better than lovastatin, and safety has no side effect.
Herba Silybi mariani hardship, cold have the effect of heat-clearing and toxic substances removing, nourishing the liver function of gallbladder promoting.Modern study shows to have stable liver plasma membrane, and the protection hepatocyte is without prejudice, and improves the effect of liver function, and serum cholesterol-lowering reduces the liver fat deposition, removes oxygen-derived free radicals in the body, to the effect of anti peroxidation of lipid and direct or indirect anti-hepatic fibrosis.Effective ingredient in the Herba Silybi mariani is mainly flavonoid, wherein mainly contains silibinin, Isosilybin, silidianin, Silychristin etc.According to modern pharmacological research; silymarin has the free radical resisting activity, removes active oxygen and antagonism lipid oxidation; suppress NO production; suppress 5 '-lipoxygenase; the protection liver plasma membrane; promote that hepatocyte is repaired, regeneration, many-sided pharmacological activity such as immunoregulation effect, the corresponding link that these effects can prevent fatty liver to take place.At present the preparation of being made by Herba Silybi mariani extract is widely used in the acute, chronic hepatitis that a variety of causes causes and the treatment of liver cirrhosis, and the control fatty liver is more satisfactory, determined curative effect, and toxic and side effects is little.
Trimethyl gallic acid, sweet, temperature is returned lung, the heart, kidney channel, has the effect of astringent or styptic treatment for spontaneous sweating, the supplementing QI for promoting the production of body fluid of convergence, kidney calming.Chinese Magnoliavine Fruit alcohol extract and deoxyschizandrin, second element, third element, pure first, pure second, ester first, ester the second grade have obvious protective effect to the animal liver cell damage that chemical toxicant causes, can suppress transaminase's release, make the active reduction of ALT.Can obvious inducing mouse and rat liver microsomes cytochrome P-450 activity.Can promote liver glycogen heteroplasia and liver glycogen to decompose.Increase the liver detoxification ability.The carbon monoxide that Fructus Schisandrae Chinensis generates after the hepatomicrosome metabolic conversion CCl4 and in metabolic process the consumption to NADPH also inhibitory action can be arranged.Fructus Schisandrae Chinensis also has enhance immunity, slow down aging, antioxidation, effects such as antitumor.
Fatty liver is owing to liver inner lipid too high levels, thereby causes the disease of abnormal liver function.So most patient's hyperlipemia and abnormal liver function are also deposited.Heavy dose of use lipid-regulation medicine as Statins, the special class of shellfish, because lipid-regulation medicine is thanked at liver mostly, raises so can cause slight transaminase, heavy dose of life-time service lipid-regulation medicine, and the transaminase certainly will further raise.Though it is normal that the result is a blood fat, liver function further worsens.And many lipid-regulation medicines may order about blood fat and more concentrate on liver metabolism, impel accumulation of lipid on the contrary and damage liver function.So in the treatment of fatty liver, answer the coupling hepatic when using fat regulation medicine.In the compositions provided by the present invention, contain Monas cuspurpureus Went extract, Fructus Schisandrae Chinensis extrat, Herba Silybi mariani extract,, utilize the synergism of three kinds of compositions, make this compositions have the effect of blood lipid regulation hepatoprotective by selection to the reasonable science of its consumption.Said composition is had in mind from transferring fat and hepatoprotective two aspects at the pathogenesis of fatty liver, and side effect is low, and the adverse consequencess such as hepatic injury of having avoided independent application lipid-regulation medicine to cause have strengthened lipid-lowering effect again, can be used for improving and the control fatty liver.The beneficial effect of compositions of the present invention is confirmed by pharmacodynamic experiment and patient's result on trial.
The specific embodiment
Below in conjunction with specific embodiment improvement and lipotropic compositions among the present invention are further described.
Embodiment 1
Improve and lipotropic compositions, it is to be made by following weight percentages:
Monas cuspurpureus Went extract (in lovastatin) 0.02,0.1,0.5,1,2,5,10 or 20
Fructus Schisandrae Chinensis extrat (in schisandrin B) 0.05,0.2,1,2,5,10,15 or 30
Herba Silybi mariani extract (in silymarin) 0.05,0.2,5,10,15,20,30 or 50
Method for making 1: get above-mentioned raw materials and be ground into fine powder,, make tablet, capsule or granule with auxiliary materials and mixing.
Method for making 2: get above-mentioned raw materials and be ground into fine powder, other gets PFG4000 heating melting, adds above-mentioned fine powder, stirs evenly, and pulverizes after the condensation, adds auxiliary materials and mixing, makes tablet, capsule or granule.
Method for making 3: get above-mentioned raw materials and be ground into fine powder, other gets PEG heating melting, adds above-mentioned fine powder, stirs evenly, and splashes in the condensed fluid, makes drop pill.
The inventory of the listed Monas cuspurpureus Went extract among this embodiment is the inventory in lovastatin, and actual feeding intake converted corresponding inventory according to the content of lovastatin in the used Monas cuspurpureus Went extract.The amount that used Monas cuspurpureus Went extract contains lovastatin during the throwing amount can be arbitrary content of 0.4～99%.
The inventory of the listed Fructus Schisandrae Chinensis extrat among this embodiment is the inventory in schisandrin B, and actual feeding intake converted corresponding inventory according to the content of schisandrin B in the used Fructus Schisandrae Chinensis extrat.The amount that used Fructus Schisandrae Chinensis extrat contains schisandrin B during the throwing amount can be arbitrary content of 0.5～99%.
The inventory of the listed Herba Silybi mariani extract among this embodiment is the inventory in silymarin, and actual feeding intake converted corresponding inventory according to the content of silymarin in the used Herba Silybi mariani extract.The moisture amount that flies silibin of used Herba Silybi mariani extract can be arbitrary content of 20～99% during the throwing amount.
Also can adopt other routine fashion to make acceptable clinically other any dosage form.
Embodiment 2
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 4%) 125g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 9%) 111g
Herba Silybi mariani extract (silymarin content is 80%) 62.5g
Method for making: get above-mentioned raw materials and be ground into fine powder, with encapsulated behind the starch 201.5g mixing, every dress 0.25g.
Using method is: oral, and each 2, every day 2～3 times.
Embodiment 3
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 1%) 250g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 15%) 65g
Herba Silybi mariani extract (silymarin content is 80%) 125g
Method for making: get above-mentioned raw materials and be ground into fine powder, with encapsulated behind the starch 60g mixing, every dress 0.25g.
Using method is: oral, and each 2, every day 2～3 times.
Embodiment 4
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 8%) 62.5g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 50%) 20g
Herba Silybi mariani extract (silymarin content is 85%) 94g
Method for making: get above-mentioned raw materials and be ground into fine powder, get 323.5gPFG4000 heating melting, add above-mentioned fine powder, stir evenly, pulverize after the condensation, incapsulate, every dress 0.25g.
Using method is: oral, and each 2, every day 2～3 times.
Embodiment 5
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 30%) 16.7g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 10%) 100g
Herba Silybi mariani extract (silymarin content is 60%) 133.3g
Method for making: get above-mentioned raw materials and be ground into fine powder, get 250gPFG4000 heating melting, add above-mentioned fine powder, stir evenly, pulverize after the condensation, incapsulate, every dress 0.25g.
Using method is: oral, and each 2, every day 2～3 times.
Embodiment 6
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 50%) 5g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 30%) 16.7g
Herba Silybi mariani extract (silymarin content is 90%) 27.8g
Method for making: get above-mentioned raw materials and be ground into fine powder, get 200.5gPFG4000 heating melting, add above-mentioned fine powder, stir evenly, pulverize after the condensation, incapsulate, every dress 0.25g.
Using method is: oral, and each 1, every day 2～3 times.
Embodiment 7
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 60%) 8.3g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 60%) 16.7g
Herba Silybi mariani extract (silymarin content is 95%) 84.2g
Method for making: get above-mentioned raw materials and be ground into fine powder, with encapsulated behind the starch 140.8g mixing, every dress 0.25g.
Using method is: oral, and each 1, every day 2～3 times.
Embodiment 8
Improve and lipotropic compositions, it is to be made by the following weight proportion raw material:
Monas cuspurpureus Went extract (lovastatin content is 90%) 5.5g
Fructus Schisandrae Chinensis extrat (schisandrin B content is 90%) 11.1g
Herba Silybi mariani extract (silymarin content is 95%) 84.2g
Method for making: get above-mentioned raw materials and be ground into fine powder,, granulate with starch 146g mixing, with micropowder silica gel 2.5g, magnesium stearate 0.75g mixing, compacting is in blocks, every heavy 0.25g.
Using method is: oral, and each 1, every day 2～3 times.
Claims (8)
1. an improvement and lipotropic compositions is characterized in that, contain Monas cuspurpureus Went extract, Fructus Schisandrae Chinensis extrat and Herba Silybi mariani extract.
2. compositions according to claim 1, it is characterized in that, described Monas cuspurpureus Went extract is 0.02～20% in its weight percentage of lovastatin, Fructus Schisandrae Chinensis extrat is 0.05～30% in its weight percentage of schisandrin B, and Herba Silybi mariani extract is 0.05～50% in its weight percentage of silymarin.
3. compositions according to claim 1, it is characterized in that, described Monas cuspurpureus Went extract is 0.1～5% in the lovastatin weight percentage, Fructus Schisandrae Chinensis extrat is 0.2～10% in the schisandrin B weight percentage, and Herba Silybi mariani extract is 0.2～20% in the silymarin weight percentage.
4. compositions according to claim 1, it is characterized in that, described Monas cuspurpureus Went extract is 1% in the lovastatin weight percentage, and Fructus Schisandrae Chinensis extrat is 2% in the schisandrin B weight percentage, and Herba Silybi mariani extract is 10% in the silymarin weight percentage.
5. according to claim 1,2,3,4 described compositionss, it is characterized in that described Monas cuspurpureus Went extract is main active with the lovastatin, lovastatin accounts for 0.4～99% by weight percentage in the Monas cuspurpureus Went extract; Described Fructus Schisandrae Chinensis extrat is a main active with the schisandrin B, and schisandrin B accounts for 5～99% by weight percentage in the Fructus Schisandrae Chinensis extrat; Described Herba Silybi mariani extract is a main active with the silymarin, and silymarin accounts for 40～99% by weight percentage in the Herba Silybi mariani extract.
6. according to claim 1,2,3,4 described compositionss, it is characterized in that described compositions is made any dosage form of acceptable clinically with acceptable adjuvant medically.
7. preparation according to claim 6 is characterized in that, said preparation can be ordinary preparation, quick releasing formulation, sustained-release preparation and other clinical acceptable preparation.
8. according to claim 1,2,3,4 described compositionss, improve and control fatty liver medicine and the application in accent fat liver-protecting health food in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007102008031A CN101062097B (en) | 2007-06-11 | 2007-06-11 | Compound for improving and treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007102008031A CN101062097B (en) | 2007-06-11 | 2007-06-11 | Compound for improving and treating fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101062097A true CN101062097A (en) | 2007-10-31 |
| CN101062097B CN101062097B (en) | 2011-05-04 |
Family
ID=38963511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007102008031A Expired - Fee Related CN101062097B (en) | 2007-06-11 | 2007-06-11 | Compound for improving and treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101062097B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647845B (en) * | 2008-08-13 | 2011-11-30 | 张晶 | Natural product composition used for reducing blood fat and preparation method thereof |
| CN104435147A (en) * | 2014-12-08 | 2015-03-25 | 南京泛成生物化工有限公司 | Composition for preventing and treating non-alcoholic fatty liver disease and application thereof |
| CN105597014A (en) * | 2016-02-05 | 2016-05-25 | 黑龙江省宏望饲料有限责任公司 | Preparation for preventing and treating fatty liver of grass carp and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100591337C (en) * | 2005-03-23 | 2010-02-24 | 张帆 | Medicinal composition for preventing alcoholic liver damage |
| CN1301665C (en) * | 2005-05-18 | 2007-02-28 | 成刚 | Blood fat-regulating liver-protecting health food |
-
2007
- 2007-06-11 CN CN2007102008031A patent/CN101062097B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647845B (en) * | 2008-08-13 | 2011-11-30 | 张晶 | Natural product composition used for reducing blood fat and preparation method thereof |
| CN104435147A (en) * | 2014-12-08 | 2015-03-25 | 南京泛成生物化工有限公司 | Composition for preventing and treating non-alcoholic fatty liver disease and application thereof |
| CN105597014A (en) * | 2016-02-05 | 2016-05-25 | 黑龙江省宏望饲料有限责任公司 | Preparation for preventing and treating fatty liver of grass carp and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101062097B (en) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091315A (en) | Ginger and dark plum fruit composition and preparation method thereof, and application of ginger and dark plum fruit composition in preparation of attenuation and synergy medicaments for radiotherapy and chemotherapy of cancers | |
| CN101053621A (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
| CN102091314A (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN101062097B (en) | Compound for improving and treating fatty liver | |
| CN1621080A (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1762441A (en) | Chinese medicine composition for treating hyperlipemia and preparing method thereof | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN103735623A (en) | Auxiliary blood fat reducing tablet | |
| CN1879788A (en) | Virus-clearing capsule | |
| CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN1686519A (en) | Medicinal composition for preventing alcoholic liver damage | |
| CN1660387A (en) | Health care preparation for regulating functional balance of organs of bowels in human body and preparing method | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1586297A (en) | Body building health preparation and its producing method | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN101028482A (en) | Stomach-clearing pill | |
| CN1839956A (en) | Pharmaceutical composition containing curcumin and its formulation | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN100340264C (en) | Pharmaceutical composition for treating hypertension and hyperlipemia and its preparation method | |
| CN102166337A (en) | Ginger and inula flower composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGXI HANHE BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: MAO XIAOMIN Effective date: 20150813 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150813 Address after: 330069 high tech Industrial Development Zone, Jiangxi, Nanchang high tech Road, D group Patentee after: Jiangxi harworld Biotechnology Co. Ltd. Address before: 330006 Jiangxi province Nanchang City Road Garden residential district Magi Magi 34 building 3 unit 301 room Patentee before: Mao Xiaomin Effective date of registration: 20150813 Address after: 330069 high tech Industrial Development Zone, Jiangxi, Nanchang high tech Road, D group Patentee after: Jiangxi harworld Biotechnology Co. Ltd. Address before: 330006 Jiangxi province Nanchang City Road Garden residential district Magi Magi 34 building 3 unit 301 room Patentee before: Mao Xiaomin |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20190611 |